Impact of Covid-19 on risk of severe maternal morbidity

Crit Care. 2023 Sep 5;27(1):344. doi: 10.1186/s13054-023-04584-6.

Abstract

Background: We examined the risk of severe life-threatening morbidity in pregnant patients with Covid-19 infection.

Methods: We conducted a population-based study of 162,576 pregnancies between March 2020 and March 2022 in Quebec, Canada. The main exposure was Covid-19 infection, including the severity, period of infection (antepartum, peripartum), and circulating variant (wildtype, alpha, delta, omicron). The outcome was severe maternal morbidity during pregnancy up to 42 days postpartum. We estimated risk ratios (RR) and 95% confidence intervals (CI) for the association between Covid-19 infection and severe maternal morbidity using adjusted log-binomial regression models.

Results: Covid-19 infection was associated with twice the risk of severe maternal morbidity compared with no infection (RR 2.02, 95% CI 1.76-2.31). Risks were elevated for acute renal failure (RR 3.01, 95% CI 1.79-5.06), embolism, shock, sepsis, and disseminated intravascular coagulation (RR 1.35, 95% CI 0.95-1.93), and severe hemorrhage (RR 1.49, 95% CI 1.09-2.04). Severe antepartum (RR 13.60, 95% CI 10.72-17.26) and peripartum infections (RR 20.93, 95% CI 17.11-25.60) were strongly associated with severe maternal morbidity. Mild antepartum infections also increased the risk, but to a lesser magnitude (RR 3.43, 95% CI 2.42-4.86). Risk of severe maternal morbidity was around 3 times greater during circulation of wildtype and the alpha and delta variants, but only 1.2 times greater during omicron.

Conclusions: Covid-19 infection during pregnancy increases risk of life-threatening maternal morbidity, including renal, embolic, and hemorrhagic complications. Severe Covid-19 infection with any variant in the antepartum or peripartum periods all increase the risk of severe maternal morbidity.

Keywords: Covid-19; Hemorrhage; Pregnancy; Renal failure; SARS-CoV-2; Severe maternal morbidity.

MeSH terms

  • COVID-19*
  • Canada
  • Disseminated Intravascular Coagulation*
  • Female
  • Humans
  • Pregnancy
  • Pregnancy Complications, Infectious*
  • SARS-CoV-2

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding